Frank Witney
About Frank Witney
Frank Witney: Senior Advisor
Frank Witney currently serves as a Senior Advisor. His extensive background in the biotechnology and life sciences sectors provides him with a wealth of experience beneficial to his advisory role. Witney's track record of leadership in various prominent organizations equips him with the industry insights needed to offer strategic guidance and support.
Frank Witney: Former President and CEO of Affymetrix, Inc.
Frank Witney served as President and Chief Executive Officer of Affymetrix, Inc. At Affymetrix, Witney specialized in microarray technology and cellular analysis. His leadership contributed to advancements in these fields during his tenure. Affymetrix, under his direction, focused on developing innovative solutions for genetic analysis, leading to significant growth and recognition in the biotechnology industry.
Frank Witney: Leadership at Dionex Corp.
Frank Witney previously held the position of President and Chief Executive Officer at Dionex Corp. Dionex is known for its expertise in ion and high-performance liquid chromatography. Under Witney's leadership, the company solidified its position as a leader in these technologies, which are critical for various scientific and industrial applications.
Career at PerkinElmer and Packard BioScience
Frank Witney's career includes significant roles at PerkinElmer and Packard BioScience. He was the President of PerkinElmer's Drug Discovery Tools division, a position he held following PerkinElmer's acquisition of Packard BioScience, where Witney served as President and Chief Operating Officer. His work in these roles involved overseeing the development and commercialization of tools essential for drug discovery and research.
Frank Witney: Board Member and Operating Partner
Frank Witney is a member of the board of directors for several publicly traded companies, including PerkinElmer, Cerus Corporation, Codex DNA, and Standard BioTools. In addition to his board memberships, he also serves as an Operating Partner at Ampersand Capital Partners. His involvement in these roles speaks to his broad expertise and the trust placed in his strategic acumen by these organizations.